London, 18 March 2013 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) today announces the signing of an exclusive ten-year collaboration and licensing agreement with Sinclair IS Pharma for Flammacerium, its leading hospital product for the prevention and treatment of infections from severe burn wounds, in the Middle East and North Africa (“MENA”) region.
18 March 2013
Flammacerium is a sterile topical cream for the treatment and prevention of infections in extensive burn wounds. The product is a silver sulfadiazine cream with cerium nitrate to reduce the occurrence of immunosuppression which can occur in severely burned patients. Under the terms of the agreement, Hikma will have the exclusive rights to register and market Flammacerium in 18 countries across MENA.
Said Darwazah, Hikma’s CEO said, "A key part of our MENA strategy is to continue expanding our network of global alliances to support us in strengthening our product portfolio. We are pleased to be partnering with Sinclair to bring Flammacerium, an excellent product which will strengthen our dermatology portfolio, to our patients in the MENA region."
Chris Spooner, CEO of Sinclair IS Pharma said, "This collaboration further demonstrates Sinclair’s ability to move our product portfolio into fast-growing emerging markets through regional partnerships. Hikma’s presence and reputation across the MENA region will enable us to rapidly progress the adoption of Flammacerium."